A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer

•Concurrent radiochemotherapy is the recommended treatment for unresectable stage III NSCLC.•There is no survival difference between induction and consolidation radiochemotherapy.•The cisplatin + docetaxel regimen gives good 2-year (44%) and 5-year (∼25%) survivals.•The role of consolidation or induction chemotherapy remains to be defined.